General Information of Drug (ID: DMCKAON)

Drug Name
PMID25656651-Compound-21a Drug Info
Cross-matching ID
PubChem CID
44225624
TTD Drug ID
DMCKAON

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [2]
Dasatinib DMJV2EK Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Approved [2]
Nilotinib DM7HXWT Chronic myelogenous leukaemia 2A20.0 Approved [3]
Asciminib DM7EVUF Chronic myeloid leukaemia 2A20 Approved [4]
Radotinib DMWA74Y leukaemia 2A60-2B33 Phase 3 [5]
ABL 001 DMMF5K4 Chronic myeloid leukaemia 2A20 Phase 3 [6]
ICLUSIG DM1SQSE Acute lymphoblastic leukaemia 2A85 Phase 3 [7]
Bafetinib DM7586F Bone disease FC0Z Phase 2 [8]
AN-019 DMJ7QP8 Chronic myelogenous leukaemia 2A20.0 Phase 2 [9]
HQP1351 DMQ30X2 Chronic myeloid leukaemia 2A20 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [2]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [11]
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [12]
Regorafenib DMHSY1I Gastrointestinal stromal tumour 2B5B Approved [13]
Ponatinib DMYGJQO Acute lymphoblastic leukaemia 2A85 Approved [13]
Pazopanib HCl DM6U9CQ Renal cell carcinoma 2C90 Approved [14]
Pexidartinib DMS2J0Z Tenosynovial giant cell tumour 2F7B Approved [15]
Ripretinib DM958QB Gastrointestinal stromal tumour 2B5B Approved [16]
Famitinib DMSFWT7 Solid tumour/cancer 2A00-2F9Z Phase 2 [17]
XL-820 DMMHX9K Solid tumour/cancer 2A00-2F9Z Phase 2 [18]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [11]
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [19]
Becaplermin DM1R5X4 Diabetic complication 5A2Y Approved [20]
E-3810 DM42PFT Solid tumour/cancer 2A00-2F9Z Phase 3 [21]
Famitinib DMSFWT7 Solid tumour/cancer 2A00-2F9Z Phase 2 [17]
XL-820 DMMHX9K Solid tumour/cancer 2A00-2F9Z Phase 2 [18]
MK-2461 DM21WBH Alzheimer disease 8A20 Phase 1/2 [22]
SNN-0031 DM2X3BR Brain injury NA07.Z Phase 1/2 [23]
TAK-593 DMNFZOT Solid tumour/cancer 2A00-2F9Z Phase 1 [24]
Pyridine derivative 18 DMBZMYT N. A. N. A. Patented [25]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fusion protein Bcr-Abl (Bcr-Abl) TTS7G69 BCR_HUMAN-ABL1_HUMAN Inhibitor [1]
Platelet-derived growth factor receptor beta (PDGFRB) TTI7421 PGFRB_HUMAN Inhibitor [1]
Tyrosine-protein kinase Kit (KIT) TTX41N9 KIT_HUMAN Inhibitor [1]

References

1 Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
2 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
3 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
4 Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019 Dec 12;381(24):2315-2326.
5 Danusertib, an aurora kinase inhibitor.Expert Opin Investig Drugs.2012 Mar;21(3):383-93.
6 ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia, NorthBuilding, 2014, 120-125.
7 Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018 Jul 26;132(4):393-404.
8 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
9 Design, synthesis and preclinical evaluation of NRC-AN-019. Int J Oncol. 2013 Jan;42(1):168-78.
10 Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors. Cell Biosci. 2019 Oct 26;9:88.
11 Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
12 New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven a... J Med Chem. 2000 Jun 15;43(12):2310-23.
13 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
14 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
15 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
16 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
17 Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
18 National Cancer Institute Drug Dictionary (drug id 452042).
19 Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
20 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
21 E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
22 MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
23 Company report (Neuronova)
24 Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism. Biochemistry. 2011 Feb 8;50(5):738-51.
25 RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.